Vivos Therapeutics, Inc. (VVOS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vivos Therapeutics, Inc. on September 18, 2024. The Company is an emerging growth company incorporated in Delaware, with principal executive offices in Littleton, Colorado. The report primarily addresses a regulatory milestone achieved on the date of filing.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific corporate event rather than periodic financial performance.
Material Changes
On September 18, 2024, the Company received U.S. Food and Drug Administration (FDA) 510(k) clearance. This clearance permits the treatment of moderate to severe obstructive sleep apnea in children aged 6 to 17 using one of the Company's proprietary CARE oral medical devices.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the context of the regulatory clearance. The primary significance is the expansion of the Company's approved indications for its pediatric sleep apnea device.
Key Facts for Investor Verification
- Verify the specific scope of the FDA 510(k) clearance for the CARE oral medical device in the pediatric population (ages 6-17).
- Review the attached press release (Exhibit 99.1) for details on commercialization plans following the clearance.
- Confirm the Company's status as an emerging growth company and its implications for financial reporting.
- Check subsequent filings for any financial impact or revenue recognition related to this new indication.